drug-discovery

To find bioactive compounds for drug discovery, search public databases like ChEMBL by target to retrieve top compounds with activity data. This allows rapid identification of potential candidates for further evaluation.

Evaluate drug-likeness by computing MW, LogP, HBD, HBA, TPSA, and rotatable bonds, then checking compliance against Lipinski Ro5 and Veber rules to flag potential liabilities like high TPSA or hERG risk.

Yes, you can check drug safety and interactions using OpenFDA data by querying FDA label data for interaction signals and safety-related notes. This provides context for ADMET interpretations and potential drug interactions.

Assess ADMET profiles for lead optimization by interpreting results using an ADMET reference guide alongside Ro5 and Veber compliance checks. This flags liabilities like high TPSA or hERG risk and suggests potential optimizations.

Yes, PubChem works with cheminformatics workflows for molecule property lookup by fetching essential properties like MW, LogP, TPSA, HBD, and HBA. This provides quick decision-making data for evaluating drug-like compounds.

Limitations of using open bioactivity data for drug discovery include relying solely on public sources like ChEMBL and PubChem, which may lack comprehensive coverage. ADMET interpretations require contextualization, and flagged liabilities like hERG risk need further validation.